Luz S Fonacier MD
Associate Professor of Allergy & Immunology, SUNY Stony Brook
Join to view full profile
120 Mineola BlvdSte 410Mineola, NY 11501
Phone+1 516-663-4751
Fax+1 516-663-2946
Dr. Fonacier is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Allergy and Immunology, 1989 - 1991
NYU Grossman School of Medicine/Brooklyn CampusResidency, Internal Medicine, 1986 - 1989
University of the Philippines College of MedicineClass of 1978
Certifications & Licensure
NY State Medical License 1985 - 2027
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Fellow ACAAI
- Past Chair ABAI, 2021
- Newsday - Top Doctors on Long Island Castle Connolly, 2010-2021
Clinical Trials
Publications & Presentations
PubMed
- Atopic dermatitis Yardstick: A new era of topical and systemic treatments.Anna De Benedetto, Mark Boguniewicz, Luz Fonacier, Jonathan Silverberg, Katrina Abuabara
Annals of Allergy, Asthma & Immunology. 2026-08-01 - 14 citationsThe International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Torsten Zuberbier, Zainab AbdulHameed Ansari, Amir H Abdul Latiff, M M Abuzakouk, Maria Socorro Agcaoili-De Jesus
Allergy. 2026-08-01 - Precision medicine in atopic dermatitis: Present and future.Luz Fonacier, Stephanie Mawhirt, Heather Stern, Emma Roellke, Sydney Singer
Annals of Allergy, Asthma & Immunology. 2026-06-13
Journal Articles
- Irritant Contact DermatitisLuz Fonacier, MD, Clinical Reviews in Allergy & Immunology
Press Mentions
Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients with Atopic DermatitisJuly 24th, 2026- New Data Show Early and Consistent Response to VTAMA® (Tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those with Associated ComorbiditiesNovember 8th, 2025
- Another COVID-19 Halloween: Keeping Kids Safe from Viruses, Allergies and AsthmaOctober 5th, 2021
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
